Basel Hassoun, MD
Urology · Oklahoma City, OKNPI 1568579308
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.5%), education and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Astellas Pharma US Inc at 41.4% of the total. Reporting peaked in 2019 at $15,064 and has fallen 95.3% since, to $715 in 2025. Among urology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $109.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$8K
- Bioness Inc$6K
- Medtronic$4K
- Myriad Genetic Laboratories, Inc.$441
- Boston Scientific$337
- Coloplast$296
- plus $1K from 22 others
Across 12 payments — averaging $2263.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$27K
What the payments were for
- Consulting fees$6123%
- Speaking & faculty fees$7,05034%
- Travel & lodging$1,8169%
- Food & beverage$4,34521%
- Education$6,63132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 49 | $8,460 |
| Bioness Inc | 1 | $5,950 |
| Medtronic(2 entities) | 41 | $3,648 |
| Myriad Genetic Laboratories, Inc. | 19 | $441 |
| Boston Scientific | 9 | $337 |
| Coloplast | 5 | $296 |
| Pfizer | 9 | $237 |
| Antares Pharma, Inc. | 10 | $175 |
| Accord Healthcare, Inc. | 8 | $165 |
| Clarus Therapeutics Inc. | 9 | $149 |
| Blue Earth Diagnostics | 3 | $52 |
| Immunitybio, Inc. | 2 | $50 |
| Teleflex LLC | 2 | $50 |
| Mission Pharmacal Company | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 2 | $43 |
| Neotract Inc. | 2 | $43 |
| Cook Medical LLC | 1 | $35 |
| Halozyme Inc | 2 | $35 |
| Tolmar Pharmaceuticals, Inc. | 2 | $34 |
| Convatec Inc. | 1 | $29 |
| Axonics, Inc. | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Urogen Pharma, Inc. | 1 | $22 |
| Urovant Sciences Inc | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$7,286
- Stimrouter for pain$5,950
- INTERSTIM$2,528
- ALTIS$149
- GENERAL BPH$125
How this compares
$20,454 in reported general payments places this provider in the 90th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lupron DepotLeuprolide Acetate | 54 | $530,713 |
| Abiraterone Acetate | 91 | $299,597 |
| MyrbetriqMirabegron | 176 | $141,424 |
| GemtesaVibegron | 91 | $73,034 |
| ElmironPentosan Polysulfate Sodium | 39 | $35,670 |
| Tamsulosin Hcl | 572 | $9,960 |
| Finasteride | 581 | $9,845 |
| Solifenacin Succinate | 103 | $7,979 |
| Bethanechol Chloride | 97 | $7,491 |
| Testosterone | 19 | $3,792 |
| Potassium Citrate ErPotassium Citrate | 80 | $3,465 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $3,384 |
| Silodosin | 42 | $3,161 |
| Testosterone Cypionate | 73 | $3,095 |
| Desmopressin Acetate | 33 | $3,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $27 | $299,59791 claims |
| Astellas Pharma US IncMyrbetriq | $8,460 | $141,424176 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $73,03491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 145 urology providers in Oklahoma.
Other urology in Oklahoma City
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Johnny HicksonOklahoma City$16K
- Michael HolzerOklahoma City$15K
- Dominic FrimbergerOklahoma City$12K
- Aaron BenhamOklahoma City$11K
- Kathryn CunninghamOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.